Back to Search
Start Over
Comparative Pharmacokinetics Between a Fixed‐Dose Combination of Pitavastatin/Valsartan 4/160 mg and the Corresponding Individual Components Through a Partial Replicated Crossover Design in Healthy Male Subjects
- Source :
- Clinical Pharmacology in Drug Development. 11:615-622
- Publication Year :
- 2022
- Publisher :
- Wiley, 2022.
-
Abstract
- Hypertension and hyperlipidemia are often comorbid, requiring combination therapies of antihypertensive drugs and antihyperlipidemia drugs. Taking 1 fixed-dose combination (FDC) may increase patient compliance rather than taking each of the drugs separately. This study aimed to evaluate the pharmacokinetic bioequivalence between an FDC of pitavastatin/valsartan 4/160 mg and the corresponding individual components. Considering that valsartan is a highly variable drug for maximum plasma concentration (C
Details
- ISSN :
- 21607648 and 2160763X
- Volume :
- 11
- Database :
- OpenAIRE
- Journal :
- Clinical Pharmacology in Drug Development
- Accession number :
- edsair.doi.dedup.....0c42d59744c09dbaaf409ad217822f98